Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients-Reference-Cited by-同舟云学术

Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients

Published:2018-04-24 Issue:4 Volume:13 Page:e0196350
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Bisagni Alessandra^ORCID,Pagano Maria,Maramotti Sally,Zanelli Francesca,Bonacini Martina,Tagliavini Elena,Braglia Luca,Paci Massimiliano,Mozzarelli Andrea,Croci Stefania

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference42 articles.

1. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification;WD Travis;J Thorac Oncol,2015

2. Epidermal growth factor receptor mutations in lung cancer;SV Sharma;Nat Rev Cancer,2007

3. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing;LV Sequist;Oncologist,2007

4. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS;GJ Korpanty;Front Oncol,2014

5. Gefitinib;M Muhsin;Nat Rev Drug Discov,2003

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential role of miRNAs in the pathogenesis of salivary gland cancer – A Focus on signaling pathways interplay;Pathology - Research and Practice;2023-07

2. Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance prediction;Frontiers in Oncology;2023-04-20

3. Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small cell lung cancer cells;Journal of Thoracic Disease;2023-04

4. MicroRNA in lung cancer—a novel potential way for early diagnosis and therapy;Journal of Applied Genetics;2023-02-23

5. Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review);International Journal of Oncology;2022-10-20